Taiwan
· Delayed Price · Currency is TWD Syngen Biotech Statistics
Total Valuation
Syngen Biotech has a market cap or net worth of TWD 3.62 billion. The enterprise value is 3.64 billion.
| Market Cap | 3.62B |
| Enterprise Value | 3.64B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Jun 26, 2025 |
Share Statistics
Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 27.10M |
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 8.15% |
| Owned by Institutions (%) | 4.31% |
| Float | 10.54M |
Valuation Ratios
The trailing PE ratio is 15.00.
| PE Ratio | 15.00 |
| Forward PE | n/a |
| PS Ratio | 1.78 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | 11.65 |
| P/OCF Ratio | 9.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.62, with an EV/FCF ratio of 11.73.
| EV / Earnings | 15.07 |
| EV / Sales | 1.79 |
| EV / EBITDA | 8.62 |
| EV / EBIT | 11.98 |
| EV / FCF | 11.73 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.63 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 1.09 |
| Interest Coverage | 36.28 |
Financial Efficiency
Return on equity (ROE) is 11.46% and return on invested capital (ROIC) is 7.53%.
| Return on Equity (ROE) | 11.46% |
| Return on Assets (ROA) | 6.14% |
| Return on Invested Capital (ROIC) | 7.53% |
| Return on Capital Employed (ROCE) | 12.91% |
| Revenue Per Employee | 8.23M |
| Profits Per Employee | 978,126 |
| Employee Count | 247 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 3.70 |
Taxes
In the past 12 months, Syngen Biotech has paid 62.87 million in taxes.
| Income Tax | 62.87M |
| Effective Tax Rate | 20.65% |
Stock Price Statistics
The stock price has decreased by -18.13% in the last 52 weeks. The beta is 0.16, so Syngen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -18.13% |
| 50-Day Moving Average | 132.13 |
| 200-Day Moving Average | 130.37 |
| Relative Strength Index (RSI) | 41.80 |
| Average Volume (20 Days) | 23,671 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech had revenue of TWD 2.03 billion and earned 241.60 million in profits. Earnings per share was 8.90.
| Revenue | 2.03B |
| Gross Profit | 732.92M |
| Operating Income | 306.18M |
| Pretax Income | 304.47M |
| Net Income | 241.60M |
| EBITDA | 408.69M |
| EBIT | 306.18M |
| Earnings Per Share (EPS) | 8.90 |
Balance Sheet
The company has 316.91 million in cash and 339.60 million in debt, giving a net cash position of -22.70 million or -0.84 per share.
| Cash & Cash Equivalents | 316.91M |
| Total Debt | 339.60M |
| Net Cash | -22.70M |
| Net Cash Per Share | -0.84 |
| Equity (Book Value) | 2.16B |
| Book Value Per Share | 79.78 |
| Working Capital | 439.89M |
Cash Flow
In the last 12 months, operating cash flow was 368.23 million and capital expenditures -57.74 million, giving a free cash flow of 310.49 million.
| Operating Cash Flow | 368.23M |
| Capital Expenditures | -57.74M |
| Free Cash Flow | 310.49M |
| FCF Per Share | 11.46 |
Margins
Gross margin is 36.07%, with operating and profit margins of 15.07% and 11.89%.
| Gross Margin | 36.07% |
| Operating Margin | 15.07% |
| Pretax Margin | 14.98% |
| Profit Margin | 11.89% |
| EBITDA Margin | 20.11% |
| EBIT Margin | 15.07% |
| FCF Margin | 15.28% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.76%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 3.76% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.09% |
| Buyback Yield | -0.01% |
| Shareholder Yield | 3.84% |
| Earnings Yield | 6.68% |
| FCF Yield | 8.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Syngen Biotech has an Altman Z-Score of 4.25 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.25 |
| Piotroski F-Score | 7 |